Evidence map›Paper›PMID 31968401›Full record

ArticleMolecular genetics & genomic medicine2020

Extending the spectrum of CLRN1- and ABCA4-associated inherited retinal dystrophies caused by novel and recurrent variants using exome sequencing.

Mohammed Abu-Ameerh, Hashim Mohammad, Zain Dardas, Raghda Barham, Dema Ali, Maysa Bijawi, Mohamed Tawalbeh, Sami Amr, Ma'mon M Hatmal, Muawyah Al-Bdour and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Mohammed Abu-AmeerhDepartment of Ophthalmology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Hashim MohammadSchool of Medicine, The University of Jordan, Amman, Jordan.ORCID 0000-0003-4769-2254
Zain DardasDepartment of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, Jordan.ORCID 0000-0003-2387-3122
Raghda BarhamCell Therapy Center, The University of Jordan, Amman, Jordan.
Dema AliCell Therapy Center, The University of Jordan, Amman, Jordan.ORCID 0000-0002-7185-5028
Maysa BijawiCell Therapy Center, The University of Jordan, Amman, Jordan.
Mohamed TawalbehDepartment of Otolaryngology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Sami AmrDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ma'mon M HatmalDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite University, Zarqa, Jordan.
Muawyah Al-BdourDepartment of Ophthalmology, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.
Belal AzabDepartment of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
University of Jordan · JOBrigham and Women's Hospital · USHashemite University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInherited retinal dystrophies (IRDs) are characterized by extreme genetic and clinical heterogeneity. There are many genes that are known to cause IRD which makes the identification of the underlying genetic causes quite challenging. And in view of the emergence of therapeutic options, it is essential to combine molecular and clinical data to correctly diagnose IRD patients. In this study, we aimed to identify the disease-causing variants (DCVs) in four consanguineous Jordanian families with IRDs and describe genotype-phenotype correlations.

methodsExome sequencing (ES) was employed on the proband patients of each family, followed by segregation analysis of candidate variants in affected and unaffected family members by Sanger sequencing. Simulation analysis was done on one novel CLRN1 variant to characterize its effect on mRNA processing. Clinical evaluation included history, slit-lamp biomicroscopy, and indirect ophthalmoscopy.

resultsWe identified two novel variants in CLRN1 [(c.433+1G>A) and (c.323T>C, p.Leu108Pro)], and two recurrent variants in ABCA4 [(c.1648G>A, p.Gly550Arg) and (c.5460+1G>A)]. Two families with the same DCV were found to have different phenotypes and another family was shown to have sector RP. Moreover, simulation analysis for the CLRN1 splice donor variant (c.433+1G>A) showed that the variant might affect mRNA processing resulting in the formation of an abnormal receptor. Also, a family that was previously diagnosed with nonsyndromic RP was found to have Usher syndrome based on their genetic assessment and audiometry.

conclusionOur findings extend the spectrum of CLRN1- and ABCA4-associated IRDs and describe new phenotypes for these genes. We also highlighted the importance of combining molecular and clinical data to correctly diagnose IRDs and the utility of simulation analysis to predict the effect of splice donor variants on protein formation and function.

Indexed as

MutationAdultATP-Binding Cassette TransportersChildExomeFemaleHumansMaleMembrane ProteinsMiddle AgedPedigreePhenotypeRetinal DystrophiesRNA SplicingABCA4 protein, humanATP-Binding Cassette TransportersCLRN1 protein, humanMembrane ProteinsABCA4CLRN1Exome sequencingInherited retinal dystrophy

Identifiers

PMID31968401
PMCPMC7057102
OpenAlexW3000916165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.